338 related articles for article (PubMed ID: 35274729)
1. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
[TBL] [Abstract][Full Text] [Related]
3. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review.
Guven DC; Sahin TK; Kilickap S; Uckun FM
Front Oncol; 2021; 11():759108. PubMed ID: 34804957
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
Uaprasert N; Pitakkitnukun P; Tangcheewinsirikul N; Chiasakul T; Rojnuckarin P
Blood Cancer J; 2022 Dec; 12(12):173. PubMed ID: 36550105
[TBL] [Abstract][Full Text] [Related]
5. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
Front Immunol; 2022; 13():892331. PubMed ID: 36003404
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
9. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
Gagelmann N; Passamonti F; Wolschke C; Massoud R; Niederwieser C; Adjallé R; Mora B; Ayuk F; Kröger N
Haematologica; 2022 Aug; 107(8):1840-1849. PubMed ID: 34911284
[TBL] [Abstract][Full Text] [Related]
10. Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination.
Sriwijitalai W; Wiwanitkit V
Oncologist; 2022 Nov; 27(11):e916. PubMed ID: 36018054
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P
Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135
[TBL] [Abstract][Full Text] [Related]
12. High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.
Shapiro LC; Thakkar A; Gali R; Gonzalez-Lugo JD; Bazarbachi AH; Rahman S; Pradhan K; Fehn K; Abreu M; Kornblum N; Gritsman K; Goldfinger M; Shastri A; Mantzaris I; Braunschweig I; Halmos B; Verma A; McCort M; Bachier-Rodriguez L; Sica RA
Leuk Lymphoma; 2022 Oct; 63(10):2484-2488. PubMed ID: 35593019
[No Abstract] [Full Text] [Related]
13. Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients.
Fattizzo B; Bortolotti M; Rampi N; Cavallaro F; Giannotta JA; Bucelli C; Cassin R; Da Vià MC; Galassi G; Noto A; Pettine L; Rossi FG; Sciumè M; Ceriotti F; Consonni D; Barcellini W; Baldini L
Front Immunol; 2022; 13():852158. PubMed ID: 35634287
[TBL] [Abstract][Full Text] [Related]
14. Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
Martins-Branco D; Nader-Marta G; Tecic Vuger A; Debien V; Ameye L; Brandão M; Punie K; Loizidou A; Willard-Gallo K; Spilleboudt C; Awada A; Piccart M; de Azambuja E
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3075-3080. PubMed ID: 35867203
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
[TBL] [Abstract][Full Text] [Related]
16. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.
Pfannes R; Pierzchalski A; Maddalon A; Simion A; Zouboulis CC; Behre G; Zenclussen AC; Westphal S; Fest S; Herberth G
Front Immunol; 2023; 14():1087996. PubMed ID: 37187728
[TBL] [Abstract][Full Text] [Related]
17. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis.
Jena A; Mishra S; Deepak P; Kumar-M P; Sharma A; Patel YI; Kennedy NA; Kim AHJ; Sharma V; Sebastian S
Autoimmun Rev; 2022 Jan; 21(1):102927. PubMed ID: 34474172
[TBL] [Abstract][Full Text] [Related]
18. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.
Piechotta V; Mellinghoff SC; Hirsch C; Brinkmann A; Iannizzi C; Kreuzberger N; Adams A; Monsef I; Stemler J; Cornely OA; Bröckelmann PJ; Skoetz N
Blood Cancer J; 2022 May; 12(5):86. PubMed ID: 35641489
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
Giuliano AR; Lancet JE; Pilon-Thomas S; Dong N; Jain AG; Tan E; Ball S; Tworoger SS; Siegel EM; Whiting J; Mo Q; Cubitt CL; Dukes CW; Hensel JA; Keenan RJ; Hwu P
JAMA Oncol; 2022 May; 8(5):748-754. PubMed ID: 35266953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
